In the last few years, chemical modification of glycopeptide antibiotics has been directed to the derivatives which would be active against highly glycopeptideresistant (VanA) enterococci while retaining activity against susceptible Gram-positive bacteria including methicillin-resistant and coagulase-negative staphylococci1). To date the most promising results have been obtained by the reductive alkylation of antibiotic LY264826 with various lipophilic aldehydes2). N-(pPhenylbenzyl), N-(n-decyl), N-(p-chlorobenzyl) and some other derivatives of LY264826 alkylated at the amino sugar disaccharide branch had demonstrated activity against both glycopeptide-resistant and susceptible
Gram-positive bacteria.
Here we report the application of the above approach to the derivatization of the glycopeptide antibiotic A-40926 (I)3,4)• I is a complex of three main factors which differ in the fatty acid chains attached to a 2-aminoglucuronyl residue (Fig. 1, Table 1 ; shown is the main factor B, whose content in complex is about 70%). The nitrogen atom at the N-terminus of the peptide in A-40926 and its derivatives is designated as N, the nitrogen atom in the 2-aminoglucuronyl residue is designated as N'. Recently, N'-deacylation of A-40926 by microbial transformation with Actinoplanes teichomyceticus ATCC 31121 has been described5). N-Boc-N'-deacyl-A-40926 (III) was obtained by a similar procedure
III is a suitable starting material for the preparation of derivatives containing different alkyl or aralkyl substituents at the amino group of the carbohydrate moiety. Besides, two carboxyl groups of III afford additional possibilities for chemical transformations, e. g. transfer to various carboxamides and esters.
The reductive alkylation of III with p-chlorobenzyl, p-phenylbenzyl or decyl aldehydes (1.5 eq.) in the presence of NaBH3CN (2 eq.) in MeOH and followed by deprotection with TFA produced corresponding N'-monoalkyl derivatives V, VI, and VII. For the synthesis of a N', N'-didecyl derivative VIII, 5 eq. of decyl aldehyde and 6 eq. of NaBH3CN were used.
A series of di-(3-dimethylaminopropyl) amides (IX, X, XI and XII) were obtained by the amidation of N Boc-N'-alkyl derivatives with 3-dimethylaminopro- pylamine (2.2 eq.) and PyBOP (2.5 eq.) as a condensing agent in DMSO followed by deprotection with TFA. Reductive alkylation, amidation and deprotection were were purified using column chromatography on Sephadex LH-20 as previously described6). The progress of the reactions, column eluates and the purity of the final compounds were checked by TLC in systems: EtOAcn-PrOH-25% NH4OH 1:1:1 or 2:1:1 and n-BuOHAcOH-H2O 5:1:1. The structures of the products were confirmed by 1H NMR and ESI-MS spectrometry. Antibacterial activity in vitro data are presented in Table 1 . The substitution of fatty acid chains in I by alkyl (VII and VIII) or aralkyl (V and VI) residues differently affects the antibacterial activity. Among the group-containing derivative V was the most active against the S. aureus and S. epidermidis clinical isolates. However, similarly to I, compound V showed poor activity against S. haemolyticus. In contrast, N'-deacyl-N'-decyl-A-40926 (VII) was more active than I against S. haemolyticus and S. epidermidis but had a low activity against S. aureus. N', N'-Didecyl (VIII) and N'-pphenylbenzyl (VI) derivatives as well as I had poor activity against clinical isolates of staphylococci. As expected, diamides IX, X, XI, and XII were more active than the corresponding starting N'-alkyl derivatives V, VI, VII, and VIII, the C10H21 moiety-containing diamide XI being the most active among the above compounds. 
